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ABSTRACT
Background Quality- adjusted life years (QALYs) are 
widely used to measure the impact of various diseases 
on both the quality and quantity of life and in their 
economic valuations. It will be clinically important 
and informative if we can estimate QALYs based on 
measurements of depression severity.
Objective To construct a conversion table from the 
Patient Health Questionnaire-9 (PHQ-9), the most 
frequently used depression scale in recent years, to the 
Euro- Qol Five Dimensions Three Levels (EQ- 5D- 3L), one 
of the most commonly used instruments to assess QALYs.
Methods We obtained individual participant data 
of randomised controlled trials of internet cognitive- 
behavioural therapy which had administered depression 
severity scales and the EQ- 5D- 3L at baseline and at 
end of treatment. Scores from depression scales were 
all converted into the PHQ-9 according to the validated 
algorithms. We used equipercentile linking to establish 
correspondences between the PHQ-9 and the EQ- 5D- 3L.
Findings Individual- level data from five trials (total 
N=2457) were available. Subthreshold depression 
(PHQ-9 scores between 5 and 10) corresponded with 
EQ- 5D- 3L index values of 0.9–0.8, mild major depression 
(10–15) with 0.8–0.7, moderate depression (15–20) 
with 0.7–0.5 and severe depression (20 or higher) 
with 0.6–0.0. A five- point improvement in PHQ-9 
corresponded approximately with an increase in EQ- 
5D- 3L score by 0.03 and a ten- point improvement by 
approximately 0.25.
Conclusions and Clinical Implications The 
conversion table between the PHQ-9 and the EQ- 5D- 3L 
scores will enable fine- grained assessment of burden of 
depression at its various levels of severity and of impacts 
of its various treatments.
INTRODUCTION
Quality- adjusted life years (QALYs) have been 
increasingly used in general medicine and in psychi-
atry to evaluate the impact of a disease on both the 
quantity and quality of life.1 One QALY is equal to 
1 year in perfect health, can range down to zero 
(death) or may take negative values (worse than 
death). QALYs can be used to compare the burdens 
of various diseases, to appreciate the impact of 
their interventions, to help set priorities in resource 
allocations across different diseases and interven-
tions and to inform personal decisions.
The representative method to evaluate QALYs 
is the generic, preference- based measure of 
health including the Euro- Qol five dimensions 
(EQ- 5D)2 3 and the SF- 6D based on Short Form 
Survey-36 (SF-36).4 5 Of these, the EQ- 5D is the 
most frequently used and is the preferred instru-
ment by the National Institute of Health and Care 
Excellence in the UK. While the responsiveness of 
such generic measures to various mental conditions, 
especially severe mental illnesses, has been ques-
tioned,6 its validity and responsiveness to common 
mental disorders including depression and anxiety 
have been generally established.7 8
However, the traditional focus of measurements 
in mental health has centred mainly on symptoms. 
Many trials have, therefore, not administered the 
generic health- related quality of life measures. This 
has hindered comparison of impacts of mental 
disorders vis-à-vis other medical conditions on the 
one hand and also evaluation of values of their 
interventions on the other.9 10
We have been collecting individual participant- 
level data from randomised controlled trials of 
internet cognitive- behavioural therapies (iCBT) 
for depression,11 several of which administered 
both symptomatologic scales and generic health 
status scales simultaneously. This study, therefore, 
attempts to link the depression- specific measure 
onto the generic measure of health in order to 
enable estimation of QALYs for depressive states 
and their changes. Such cross- walking should 
facilitate assessment of burden of depression at its 




We have been accumulating a data set of individual 
participant data of randomised controlled trials 
of iCBT among adults with depressive symptoms, 
as established by specified cut- offs on self- report 
scales or by diagnostic interviews.11 For this study, 
we have selected studies that have administered the 
EQ- 5D and depression severity scales at baseline 
and at end of treatment. We excluded patients if 
2 Furukawa TA, et al. Evid Based Ment Health 2021;0:1–5. doi:10.1136/ebmental-2020-300240
Health economics
they had missing data in either of the two scales at baseline or 
at endpoint. We excluded studies that focused on patients with 




The EQ- 5D- 3L comprises five dimensions of mobility, self- care, 
usual activities, pain/discomfort and anxiety/depression, each rated 
on three levels corresponding with 1=no problems, 2=some/
moderate problems or 3=extreme problems/unable to do. This 
produces 3ˆ5=243 different health states, ranging from no 
problem at all in any dimension (11111) to severe problems on 
all dimensions (33333). Each of these 243 states is provided with 
a preference- based score, as determined through the time trade- off 
(TTO) technique in a sample of the general population. In TTO, 
respondents are asked to give the relative length of time in full 
health that they would be willing to sacrifice for the poor health 
states as represented by each of the 243 combinations above. 
The EQ- 5D scores range between 1=full health and 0=death to 
minus values=worse than death bounded by −1. The scoring algo-
rithm for the UK is based on TTO responses of a random sample 
(n=2997) of noninstitutionalised adults. Over the years, value sets 
for EQ- 5D- 3L have been produced for many countries/regions.2 3 7
Depression severity scales
We included any validated depression severity measures. The 
scale scores were converted into the most frequently used scale, 
namely, the Patient Health Questionnaire-9 (PHQ-9),12 using the 
established conversion algorithms13 14 for the Beck Depression 
Inventory, second edition (BDI- II)15 or the Centre for Epidemio-
logic Studies Depression Scale (CES- D).16
The PHQ-9 consists of the nine diagnostic criteria items 
of major depression from the DSM- IV, each rated on a scale 
between 0 and 3, making the total score range 0–27. The instru-
ment has demonstrated excellent reliability, validity and respon-
siveness. The cut- offs have been proposed as 0–4, 5–9, 10–14, 
15–19 and 20- for no, mild, moderate, moderately severe and 
severe depression, respectively.12
Statistical analyses
We first calculated Spearman correlation coefficients between 
PHQ-9 and EQ- 5D total scores at baseline, at end of treatment 
and their changes, to establish if the linking is justified. Correla-
tions were considered weak if scores were <0.3, moderate if 
scores were ≥0.3 and<0.7 and strong if scores were ≥0.7.17 
Correlations ≥0.3 have been recommended to establish linking.18 
We then applied the equipercentile linking procedure,19 which 
identified scores on PHQ-9 and EQ- 5D or their changes with the 
same percentile ranks and allows for a nominal translation from 
PHQ-9 to EQ- 5D by using their percentile values. This approach 
has been used successfully for scales in depression, schizophrenia 
or Alzheimer’s disease.14 20–22 We analysed all trials collectively 
rather than by trial to maximise the sample size, ensure vari-
ability in the included populations and attain robust estimates.
We conducted a sensitivity analysis by excluding studies that 
require the conversion of various depression severity scores into 
PHQ-9.
All the analyses were conducted in R V.4.0.2, with the package 
equate V.2.0.7.23
Ethics statement
The authors assert that all procedures contributing to this work 
comply with the ethical standards of the relevant national and 
institutional committees on human experimentation and with 
the Helsinki Declaration of 1975, as revised in 2008. Ethical 




We identified seven RCTs of iCBT (total n=2457), which 
administered validated depression scales and EQ- 5D both at 
baseline and at endpoint (online supplemental eTable 1). Three 
studies included only patients with major depressive disorder 
(MDD), one only patients with subthreshold depression and 
the remaining three included both. All the studies administered 
EQ- 5D- 3L. PHQ-9 scores were converted from the BDI- II 
in three studies24–26 and from the CES- D in one study.27 The 
mean age of the participants was 41.8 (SD=12.3) years, 66.0% 
(1622/2457) were women and they scored 14.0 (5.4) on PHQ-9 
and 0.74 (0.20) on EQ- 5D at baseline and 9.1 (6.0) and 0.79 
(0.21), respectively, at endpoint. When using the standard cut- 
offs of the PHQ-9,12 2.4% (60/2449) suffered from no depres-
sion (PHQ-9 scores <5), 20.2% (492/2449) from subthreshold 
depression (5≤PHQ-9 scores <10), 33.5% (820/2449) from 
mild depression (10≤PHQ-9 scores <15), 26.5% (649/2449) 
from moderate depression (15≤PHQ-9 scores <20) and 17.3% 
(424/2449) from severe depression (20≤PHQ-9 scores) at 
baseline.
Equipercentile linking
Spearman’s correlation coefficient between the PHQ-9 and the 
EQ- 5D scores was r=−0.29 at baseline, increased to r=−0.50 
after intervention and was r=−0.38 for change scores.
Figure 1 shows the equipercentile linking between PHQ-9 and 
EQ- 5D total scores at baseline and at endpoint. Figure 2 shows 
the same between their change scores. Table 1 summarises the 
correspondences between the two scales.
Sensitivity analysis
When we limited the samples to the three studies28–30 that 
administered PHQ-9 (total n=1375), the linking results were 
replicated (online supplemental eFigure 1).
Figure 1 PHQ-9 and EQ- 5D total scores at baseline and endpoint. EQ- 
5D,Euro- Qol Five Dimensions; PHQ-9, PatientHealth Questionnaire-9.
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DISCUSSION
This is the first study to link a depression severity measure with 
the EQ- 5D- 3L both for total and change scores. To summarise, 
subthreshold depression corresponded with EQ- 5D- 3L index 
values of 0.9–0.8, mild major depression with 0.8–0.7, moderate 
depression with 0.7–0.5 and severe depression with 0.6–0.0. A 
five- point improvement in PHQ-9 corresponded approximately 
with an increase in EQ- 5D- 3L index values by 0.03, and a ten- 
point improvement can lead to an increase by approximately 
0.25.
A systematic review of utility values for depression31 found 
that the pooled mean (SD) utilities based on studies using the 
standard gamble as a direct valuation method were 0.69 (0.14) 
for mild, 0.52 (0.28) for moderate and 0.27 (0.26) for severe 
major depression. The estimates based on studies using EQ- 5D 
as an indirect valuation method were 0.56 (0.16) for mild, 0.52 
(0.28) for moderate and 0.25 (0.15) for severe depression. One 
recent study regressed PHQ-9 on SF- 6D scores among 394 
patients in theimproving Access to Psychological Therapies 
(IAPT) cohort7 32 and estimated none/mild depression on PHQ-9 
to be worth 0.73 SF- 6D scores, moderate depression 0.65 and 
severe depression 0.56. Our results are largely in line with these 
aforementioned studies.
There was a consistent difference of about 0.07 EQ- 5D 
scores for the same PHQ-9 score if it represented the baseline 
or endpoint measurements (figure 1). This is understandable 
because a patient would rate their health status less satisfactory 
if they stayed equally symptomatic as before after the treatment 
and also because it means that they continued to suffer from 
depression for longer. It is, therefore, reasonable to use the 
conversion table at baseline for relatively new cases of depression 
and that at end of treatment for more chronic cases (table 1).
An effect size to be typically expected after 2 months of antide-
pressant pharmacotherapy33 or psychotherapy27 34 over the pill 
placebo condition is 0.3. Given that the average SD of PHQ-9 
in the studies was about 6, an effect size of 0.3 corresponds to a 
difference by two points on PHQ-9. The differences in EQ- 5D 
scores corresponding with the end- of- treatment PHQ-9 scores 
of x versus x+2, where x is between 5 and 15 (table 1), ranges 
between 0.08 and 0.13, producing an approximate average of 
0.1 EQ- 5D scores. If we assume that the same difference would 
continue for the ensuing 10 months, the gain in QALY per year 
would be equal to 0.09 QALY; if we assume that the difference 
would eventually wear out over the course of the year due to 
naturalistic improvements to be expected in the control group, 
the gain in QALY per year would be equal to 0.05 QALY. (See 
figure 3 for a schematic drawing to help understand the calcula-
tion of QALYs based on changing EQ- 5D scores. In reality, the 
changes will be more smoothly curvilinear but the calculation will 
be similar.) Since one QALY is typically valuated at US$50 000 
or 3000 Stirling pounds,35 such therapies would be cost- effective 
if they cost US$2500 to US$4500 (150 to 270 pounds) or less. 
If a 1 day fill of generic selective serotonergic reuptake inhibitor 
Figure 2 PHQ-9 change scores and EQ- 5D change scores. EQ- 5D,Euro- 
Qol Five Dimensions; PHQ-9, PatientHealth Questionnaire-9.
Table 1 Conversion table from PHQ-9 to EQ- 5D total and change 
scores
Total scores Change scores
PHQ-9 EQ- 5D pretreatment EQ- 5D post- treatment PHQ-9 EQ- 5D
0 – 1.00 −25 0.900
1 1.00 1.00 −24 0.850
2 1.00 1.00 −23 0.850
3 1.00 0.91 −22 0.742
4 1.00 0.89 −21 0.708
5 1.00 0.88 −20 0.683
6 0.91 0.85 −19 0.675
7 0.89 0.84 −18 0.643
8 0.88 0.81 −17 0.632
9 0.85 0.80 −16 0.609
10 0.84 0.77 −15 0.575
11 0.83 0.75 −14 0.532
12 0.80 0.72 −13 0.454
13 0.77 0.72 −12 0.401
14 0.77 0.69 −11 0.319
15 0.73 0.68 −10 0.238
16 0.72 0.65 −9 0.196
17 0.69 0.62 −8 0.143
18 0.69 0.55 −7 0.094
19 0.65 0.38 −6 0.047
20 0.57 0.36 −5 0.031
21 0.41 0.29 −4 0.016
22 0.34 0.24 −3 0.002
23 0.27 0.17 −2 −0.013
24 0.23 0.12 −1 −0.026
25 0.17 0.02 0 −0.038
26 0.10 – 1 −0.047
















EQ- 5D, Euro- Qol Five Dimensions; PHQ-9, Patient Health Questionnaire-9.
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antidepressants costs 1–3 dollars and a 1- year prescription costs 
US$400–1200 dollars, or if 8–16 sessions of psychotherapy cost 
US$1600–3200 dollars, both therapies would be deemed largely 
cost- effective. An individual’s decision, by contrast, will and 
should be more variable and no one can categorically reject nor 
require such treatments for all patients.
Several caveats should be considered when interpreting the 
results. First, our sample was limited to participants of trials of 
iCBT. It may be argued that the results, therefore, would not 
apply to patients with depression undergoing other therapies 
or in other settings. Second, the correlations between PHQ-9 
and EQ- 5D were strong enough for total scores at endpoint and 
for change scores to justify linking but were somewhat weaker 
at baseline, probably due to limited variability in PHQ-9 scores 
at baseline because some studies required minimum depres-
sion scores. However, the overall correspondence between 
PHQ-9 scores and EQ- 5D had the same shape between base-
line and endpoint, which will increase credibility of the linking 
at baseline as well. Third, we were able to compare PHQ-9 to 
EQ- 5D- 3L only. The EQ- 5D- 5L, which measures health in five 
levels instead of three, has been developed to be more sensitive 
to change and to milder conditions.36 When data become avail-
able, we will need to link PHQ-9 and EQ- 5D- 5L to examine if 
we can obtain similar conversion values.
Our study also has several important strengths. First, our 
sample included patients with subthreshold depression and 
major depression and from the community or workplace and 
the primary care. Furthermore, they encompassed mild through 
severe major depression in approximately equal proportions. 
Second, all the patients in our sample received iCBT or control 
interventions including care as usual. Potential side effects of 
different antidepressants, repetitive brain stimulation, electro-
convulsive therapy and other more aggressive therapies must 
of course be taken into consideration when evaluating their 
impacts, but our estimates, arguably independent of major side 
effects, can better inform such considerations. Finaly, unlike any 
prior studies, we were able to link specific PHQ-9 scores and 
their changes scores to EQ- 5D- 3L index values.
CONCLUSION AND CLINICAL IMPLICATIONS
In conclusion, we constructed a conversion table linking the 
EQ- 5D, the representative generic preference- based measure of 
health status, and the PHQ-9, one of the most popular depres-
sion severity rating scale, for both its total scores and change 
scores. The table will enable fine- grained assessment of burden 
of depression at its various levels of severity and of impacts of its 
various treatments which may bring various degrees of improve-
ment at the expense of some potential side effects.
Author affiliations
1Department of Health Promotion and Human Behavior, Kyoto University Graduate 
School of Medicine / School of Public Health, Kyoto, Japan
2Department of Community Mental Health, Faculty of Social Welfare and Health 
Sciences, University of Haifa, Haifa, Israel
3Department of Clinical Psychology and Psychotherapy, Friedrich- Alexander- 
University Erlangen- Nuremberg, Erlangen, Germany
4Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public 
Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
5Department of Health Sciences, University of York, York, UK
6Population Health Sciences & National Institute for Health Research Bristol 
Biomedical Research Centre, University of Bristol, Bristol, UK
7Primary Health Care, School of Public Health and Community Medicine, Institute of 
Medicine, University of Gothenburg, Gothenburg, Sweden
8Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
9Aragon Institute for Health Research (IIS Aragón), Miguel Servet University Hospital, 
Zaragoza, Spain
10Primary Care Prevention and Health Promotion Research Network, RedIAPP, 
Madrid, Spain
11Faculty of Medicine, School of Public Health, Imperial College London, London, UK
12School of Sociology & Social Policy and Institute of Mental Health, University of 
Nottingham, Nottingham, UK
Twitter Toshi A Furukawa @Toshi_FRKW and Stephen Z Levine @szlevine
Contributors TAF and EK conceived the study. TAF and SZL designed the study. 
PC and EK selected the studies and collected, cleaned and combined the IPD. CBu, 
DDE, SG, SB, DK, MK, CBj, AK, AvS, HR, JM- M, JG- C, RP and JS contributed to the 
IPD. SZL and TAF analysed the data and interpreted the results. TAF wrote the initial 
draft manuscript, and all authors provided critical input and revisions to the draft 
manuscript and approved the final manuscript.
Funding This study was supported in part by JSPS Grant- in- Aid for Scientific 
Research (grant number 17K19808) to TAF. EK was supported by the Netherlands 
Organisation for Health Research and Development (NWO; project number 
019.182SG.001). JM- M is supported by the WellcomeTrust Grant (104908/Z/14/Z).
Disclaimer The views expressed are those of the authors and not necessarily those 
of any of the funding agencies listed above.
Competing interests TAF reports grants and personal fees from Mitsubishi- 
Tanabe, personal fees from MSD, personal fees from Shionogi, outside the submitted 
work; In addition, TAF has a patent 2018-177688 concerning smartphone CBT apps 
pending, and intellectual properties for Kokoro- app licensed to Tanabe- Mitsubishi. 
JMM is supported by the Wellcome Trust Grant (104908/Z/14/Z).
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. The 
overall database used for this IPD is restricted due to data sharing agreements with 
the research institutes where the studies were conducted. IPD from individual studies 
are available from the individual study authors.
Supplemental material This content has been supplied by the author(s). It 
has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have 
been peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Figure 3 A schematic graph showing gains in QALY due to typical 
pharmacotherapies or psychotherapies. A patient may start with PHQ-
9 of 20, corresponding with EQ- 5D index value of 0.5. Then they may 
improve after 2 months of antidepressant therapy to EQ- 5D score of 
0.9 (solid line), while they may improve to EQ- 5D score of 0.8 even 
if on placebo (dashed line). If we assume that the same difference 
would continue for the ensuing 10 months while showing slow gradual 
improvement in both cases, the gain in QALY per year would be equal 
to 0.09 QALY; if we assume that the difference would eventually wear 
out over the course of the year due to naturalistic improvements to be 
expected in the control group, the gain in QALY per year would be equal 
to 0.05 QALY. Please note that this is a schematic drawing for illustrative 
purposes: in reality, the changes will be more smoothly curvilinear but 
the calculation will be similar. EQ- 5D,Euro- Qol Five Dimensions; PHQ-9, 
PatientHealth Questionnaire-9; QALY, quality- adjustedlife years.
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